Cargando…
Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
BACKGROUND: The current expert view of the PCSK9 inhibitors’ use in Egypt is still ambiguous. MAIN BODY: Hyperlipidemia is an important, if not the most important, risk factor for the occurrence of atherosclerosis worldwide. Egypt is the most populous country in the Middle East and North Africa and...
Autores principales: | Reda, Ashraf, Elserafy, Ahmed Shawky, Farag, Elsayed, Mostafa, Tamer, Farag, Nabil, Elbahry, Atef, Sanad, Osama, Bendary, Ahmed, Elkersh, Ahmed, Selim, Mohammed, Beshay, Morad, Khamis, Hazem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235146/ https://www.ncbi.nlm.nih.gov/pubmed/32424543 http://dx.doi.org/10.1186/s43044-020-00058-0 |
Ejemplares similares
-
The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022) -
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015) -
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
por: O’Connell, Emma M., et al.
Publicado: (2020) -
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
por: Athavale, Dipti, et al.
Publicado: (2018) -
Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome
por: Metkus, Thomas S., et al.
Publicado: (2022)